Brainstorm Cell Therapeutics Inc BCLI:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 09/30/22 EDT
4.42UNCH (UNCH)
Volume
414
Close
4.42quote price arrow up+0.25 (+6.00%)
Volume
468,758
52 week range
2.52 - 4.70
Loading...
  • Open4.20
  • Day High4.56
  • Day Low4.13
  • Prev Close4.17
  • 52 Week High4.70
  • 52 Week High Date08/15/22
  • 52 Week Low2.52
  • 52 Week Low Date07/29/22

Key Stats

  • Market Cap161.29M
  • Shares Out36.49M
  • 10 Day Average Volume0.26M
  • Dividend-
  • Dividend Yield-
  • Beta-0.17
  • YTD % Change10.5

KEY STATS

  • Open4.20
  • Day High4.56
  • Day Low4.13
  • Prev Close4.17
  • 52 Week High4.70
  • 52 Week High Date08/15/22
  • 52 Week Low2.52
  • 52 Week Low Date07/29/22
  • Market Cap161.29M
  • Shares Out36.49M
  • 10 Day Average Volume0.26M
  • Dividend-
  • Dividend Yield-
  • Beta-0.17
  • YTD % Change10.5

RATIOS/PROFITABILITY

  • EPS (TTM)-0.66
  • P/E (TTM)-6.72
  • Fwd P/E (NTM)-12.45
  • EBITDA (TTM)-24.273M
  • ROE (TTM)-125.86%
  • Revenue (TTM)0.00
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date11/14/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Brainstorm Cell Therapeutics Inc

 

Profile

MORE
Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is focused on the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), Alzheimer's disease (AD), and other neurodegenerative diseases. NurOwn, its cell therapy platform, leverages cell culture methods to induce autologous...
Jacob Frenkel Ph.D.
Independent Chairman of the Board
Chaim Lebovits
Chief Executive Officer
Ralph Kern M.D.
President, Chief Medical Officer
David Setboun
Chief Operating Officer, Executive Vice President
Alla Patlis CPA
Chief Financial Officer, Controller
Uri Yablonka
Executive Vice President, Chief Business Officer, Secretary, Director
Address
1325 Avenue Of Americas, 28Th Floor
New York, NY
10019
United States

Top Peers

SYMBOLLASTCHG%CHG
VIRX
Viracta Therapeutics Inc
4.27+0.18+4.40%
CVM
CEL-SCI Corp
3.10-0.35-10.14%
ANIX
Anixa Biosciences Inc
4.92+0.36+7.89%
CMRX
Chimerix Inc
1.93+0.08+4.32%
SVRA
Savara Inc
1.55+0.04+2.65%